The vote is done. On July 23-24, 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended six of seven research peptides for the 503A Bulk Drug Substances List — BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon — and rejected DSIP (emideltide). Per-peptide tallies and sourcing: FDA Panel Backs 6 Peptides for Compounding, Rejects DSIP.
Two things the headlines get wrong, and they are the whole story for buyers: the votes are advisory and non-binding — the FDA makes the final call, and its own career scientists had recommended against all seven — and nothing about sourcing changed on the day of the vote. The guide below maps what each outcome does and does not mean for access.
The original lineup put to the panel: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. The committee's recommendation decides whether licensed compounding pharmacies get a legal pathway to dispense these — or whether the grey market stays the only route.
This is the most consequential peptide regulatory event of the year, and the outcome map matters more than the headline. Here is exactly what each vote result means for access, and where each peptide stands right now.
Research-context information only. BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon are research peptides sold for research purposes only. Regulatory details and timelines below come from public FDA records and reporting. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the FDA committee is actually deciding
The PCAC reviewed whether these seven belong on the 503A Bulk Drug Substances List — the list that lets compounding pharmacies prepare a substance against an individual prescription. Day 1 (July 23) covered BPC-157, TB-500, KPV, and MOTS-c; all four were recommended. Day 2 (July 24) covered DSIP (also called emideltide), Semax, and Epitalon — Semax and Epitalon were recommended, DSIP was not. The full docket is FDA-2025-N-6895; the public comment window closed July 22.
A key detail the headlines miss: all seven already came off the FDA's Category 2 "may not be compounded" list on April 23, 2026. That reclassification is what teed them up for this review. So the July vote is not a re-ban risk. It is an upside vote — the question is whether a new legal compounding channel opens, not whether the current one closes.
The FDA plans to publish its briefing documents no later than two business days before the meeting, around July 21. Those documents will be the clearest government analysis yet of each peptide's identity, manufacturing, safety data, and the nominated indications (BPC-157's nomination centers on ulcerative colitis, for example). The committee then votes substance by substance — these are not bundled, so the seven can split.
What each outcome means for access
Industry watchers expect a mixed result — one or two favorable recommendations, the rest deferred or rejected. Here is how each path plays out for someone trying to source these peptides:
If a peptide gets a favorable vote. A "yes" recommendation does not flip access overnight. The FDA still has to issue formal rulemaking before compounding pharmacies can act on it, and that process realistically runs into late 2026 or Q1 2027. Even in the best case, prescription-based compounded supply is months away. Until then, the existing research-use-only market is unchanged.
If a peptide is deferred. Deferral kicks the substance to a later PCAC meeting — additional peptides are already slated for a session before the end of February 2027. No legal compounding pathway opens in the meantime. Sourcing stays exactly where it is today.
If a peptide gets a negative vote. A "no" does not re-criminalize anything that came off Category 2 in April. It means the FDA declines to add a compounding pathway, and demand stays in the research-use-only channel indefinitely.
The practical takeaway for buyers is the same across all three: the July vote does not change current access or pricing. Compounded pharmacy supply, if it ever arrives, is a 2027 story at the earliest. The peptides people are buying today are sourced the same way next week as they were last week.
Where to buy the 7 peptides under review
Every one of the seven is carried by research-use-only vendors right now, and the July meeting changes none of that pricing or availability. Compare live cost-per-mg, COA verification, and current coupons per peptide below — each card routes to that peptide's ranked vendor page.
